Alawadhi Yusuf, Abdolall Ali, Cunningham Christopher, Valente Megan, Fontana Robert J, Balakumaran Kathir
Department of Medicine Michigan Medicine, Ann Arbor, MI.
Summa Health System/NEOMED, Cleveland, OH.
ACG Case Rep J. 2025 Aug 4;12(8):e01799. doi: 10.14309/crj.0000000000001799. eCollection 2025 Aug.
Sodium glucose cotransporter 2 inhibitors are generally safe medications, with labelled indications for diabetes mellites, heart failure, and chronic kidney disease. We present a case of suspected dapagliflozin-induced liver injury in a 68-year-old man who presented with 2 weeks of upper abdominal pain, myalgias, and transaminitis following a prior episode of unexplained hepatitis. It was determined that the patient's liver injury with jaundice was likely due to dapagliflozin with a Revised Electronic Causality Assessment Method (RECAM) score of 9 (Highly likely). Laboratory findings and clinical symptoms resolved after discontinuing dapagliflozin during follow up.
钠-葡萄糖协同转运蛋白2抑制剂通常是安全的药物，其标签适应证为糖尿病、心力衰竭和慢性肾脏病。我们报告一例68岁男性疑似达格列净所致肝损伤的病例，该患者在先前一次不明原因肝炎发作后出现了2周的上腹部疼痛、肌痛和转氨酶升高。经判定，该患者伴有黄疸的肝损伤很可能是由达格列净引起的，采用修订后的电子因果关系评估方法（RECAM）评分为9分（极有可能）。随访期间停用达格列净后，实验室检查结果和临床症状均得到缓解。
